PERCH - PartnERship to Contrast HPV
HPV can cause cervical cancer in women and anogenital and head and neck cancers in both sexes. HPV 16 and HPV 18 genotypes cause around 70% of cases of cervical cancer, which kills around 26 000 women a year in Europe.
Cervical cancer is highly preventable through HPV vaccination and screening. However, in 2020 vaccination programme coverage in the WHO European region was only 31%.
PERCH supports national HPV vaccination efforts by improving:
- EU Member State capacities to plan and implement vaccination campaigns;
- HPV vaccination and cervical cancer screening data and monitoring systems;
- awareness of HPV-related disease and its prevention among adolescents;
- healthcare professionals’ abilities to communicate the need for vaccination.
- Project duration
- 1 Nov 2022 - 30 Apr 2025
- Project locations
- Overall budget
- €4 750 000
- EU contribution
- €3 800 00080% of the overall budget
- EU4health - Projects
- Increased awareness of how HPV vaccination and cervical cancer screening are implemented and monitored in Member States.
- Increased awareness of the benefits of HPV vaccination among target groups.
- Stronger national and international stakeholder networks.
- Empowerment of countries to obtain HPV vaccines at the lowest possible price.
- Increased HPV vaccine coverage in all or most European countries.
- European cervical cancer incidence of less than four per 100 000 per year.
- Reduced incidence of all HPV-related cancers and associated mortality in Europe.